Patients with #fibrodysplasiaossificansprogressiva (FOP) in the #US will soon have the option of treatment with another #dailypill after the #FDA approved #MirumPharma's ALK2 inhibitor, Atebrioz, for the #rarebonedisease.

pharmaphorum.com/news/fda-app...